News
-
-
PRESS RELEASE
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates
Jaguar Health, Inc. (NASDAQ:JAGX) to file Earnings Report on Form 10-Q for quarter ended September 30, 2025. Investor webcast on November 17, 2025 at 8:30 a.m. Eastern to review financials and provide corporate updates -
-
PRESS RELEASE
Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting
Crofelemer shows promising results in reducing total parenteral support for MVID patients, presented at NASPGHAN. Jaguar Health's investigation explores breakthrough benefits for pediatric patients with intestinal failure -
-
PRESS RELEASE
REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrit
Ongoing trial of crofelemer in UAE shows reduction in parenteral support for pediatric intestinal failure patients. Breakthrough in MVID and SBS-IF treatment -
-
PRESS RELEASE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. (NASDAQ:JAGX) granted RSUs to new employees effective October 20, 2025. RSUs vest over one year. The Company focuses on developing prescription medicines from rainforest plants for gastrointestinal distress -
-
PRESS RELEASE
Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals provides update on ongoing clinical trial for the treatment of MVID in pediatric patients, showing significant reduction in parenteral support in UAE. FDA advice sought for study advancement
